Health ConditionsThe sleep onset process is a complex transition from wakefulness to sleep, characterized by progressive modifications at the subjective, behavioural, cognitive, and physiological levels. More specifically, sleep onset latency (SOL) is the time it takes to actually fall asleep once a person has decided to initiate sleep β or more formally, the length of time required for the full transition from wakefulness to sleep.
Sleep onset is defined by the American Academy of Sleep Medicine as the first appearance of any 30-second epoch that contains at least 15 seconds of sleep. To this date, there is no international consensus which could aid a principled characterization of this process for clinical research purposes. Sleep onset latency is often used as a biomarker for sleepiness and in diagnostics of insomnia, and it is part of the determination of sleep efficiency and total sleep time.
Normal sleep onset latency is often between 13 and 19 minutes for adults between the ages of 20 and 50. Significant variation in these numbers is often an indication of a sleep disorder. For example, longer latencies are associated with sleep onset insomnia, a condition describing chronic difficulty falling asleep. A more recent systematic review calculated normal sleep latency in adults at approximately 11.7 minutes (95% CI: 10.8β12.6 min).
In normal adult sleep, the first sleep state after wakefulness coincides with the lightest stage β stage 1 of non-REM (NREM) sleep. The human body cycles through two phases of sleep β rapid eye movement (REM) and nonrapid eye movement (NREM), which is further divided into three stages (N1 to N3). Each phase and stage includes variations in muscle tone, brain wave patterns, and eye movements. The body cycles through all stages approximately 4 to 6 times each night, averaging 90 minutes per cycle.
Research has examined the relationship between subjective sleep onset latency (SOL), sleep structure, changes in skin and body temperature, and subjective evaluation of sleep in healthy young adults. Most participants estimated their sleep latency as being longer than their actual SOL (13.7 versus 7.6 minutes). Some insomniacs have abnormalities in time estimation function and suffer from sleep state misperception β a discrepancy between subjective and objective sleep time β and they often overestimate their sleep onset latency.
Sleep generation and maintenance are regulated by the interaction of two primary neural systems: the homeostatic sleep drive and the circadian rhythm. The homeostatic process reflects the body's accumulating need for sleep, while the circadian rhythm functions as an internal clock that regulates the sleepβwake cycle. Sleep initiation occurs primarily within the ventrolateral preoptic nucleus of the anterior hypothalamus, which inhibits several arousal-promoting centers of the brain, including the tuberomammillary nucleus, lateral hypothalamus, locus coeruleus, dorsal raphe nucleus, laterodorsal tegmental nucleus, and pedunculopontine tegmental nucleus.
Gamma-aminobutyric acid (GABA) acts as the primary inhibitory neurotransmitter of the central nervous system (CNS) and plays a central role in the suppression of arousal at sleep onset. The traditional view of sleep as a discrete and distinct state from wakefulness has been more recently challenged, and a co-existence of sleep and wake patterns in different cortical and subcortical regions has been demonstrated. In this context, the neurophysiologic landscape of a complex and progressive transitory process between wakefulness and sleep may require an authoritative, multimodal parameter definition.
At night there is a gradual decline in body temperature, a decrease in heat production, and an increase in heat loss, all of which promote sleep onset and maintenance, as well as EEG slow-wave activity. Stepwise regression analysis has shown that the degree of reduction of distal-proximal skin temperature gradient (ΞDPG) before and after lights-off was the strongest predictive factor in explaining the length of subjective sleep onset latency. The degree of heat dissipation before falling asleep contributed most to the sensation of falling asleep in healthy young adults.
Plasma levels of most hormones exhibit significant 24-hour rhythms, pointing to the importance of both the circadian clock and sleep-specific influences on their release and/or metabolism. Some hormones are little influenced by sleep versus wakefulness, including adrenocortotropic hormone, cortisol, and melatonin; some are strongly influenced by sleep, such as thyroid-stimulating hormone (TSH) and prolactin; and some are affected by particular sleep stages, such as growth hormone. Under normal conditions, prolactin levels are low during the daytime and high during sleep at night. Studies using daytime naps or sudden changes in sleep schedule have shown that sleep onset, regardless of time of day, is associated with a stimulation of prolactin release.
Sleep quality and time spent in each sleep stage may be altered by depression, aging, traumatic brain injuries, medications, and circadian rhythm disorders. Factors related to sleep onset latency include depression and fatigue. Factors significantly associated with insomnia severity also include fasting blood glucose and depression.
A systematic review and meta-analysis investigated the effect of caffeine on the characteristics of night-time sleep, with 24 studies included. Caffeine consumption reduced total sleep time by 45 minutes and sleep efficiency by 7%, with an increase in sleep onset latency of 9 minutes and wake after sleep onset of 12 minutes. The duration and proportion of light sleep (N1) increased with caffeine intake and the duration and proportion of deep sleep (N3/N4) decreased. To avoid reductions in total sleep time, coffee should be consumed at least 8.8 hours prior to bedtime, and a standard serve of pre-workout supplement at least 13.2 hours prior.
In mature adults, alcohol decreases sleep onset latency and sleep efficiency, and increases wake after sleep onset. It also increases slow-wave sleep (SWS) and decreases REM sleep in the first half of the night, with the inverse occurring in the second half. The average SOL for no-dose nights in studies of rested, healthy controls was around 15 minutes. Intoxicating doses of alcohol appear to lead to a modest reduction of SOL by approximately 5 minutes at doses β₯0.9 g/kg. Although this effect may seem small, even zolpidem sometimes shows effects of similar magnitude when administered to healthy controls. Alcohol thus may accelerate initial sleep onset while significantly degrading sleep architecture and quality overall.
Smokers had higher odds of longer sleep latency. In a cross-sectional survey of Brazilian adults, smoking increased sleep latency by approximately 12 minutes (95% CI = 5.66, 19.10; p < 0.001).
Naps lasting more than 30 minutes, having dinner as the largest meal, and all variables related to evening screen exposure (screen time before bed, use of electronic devices to fall asleep, and sleeping with screens turned on) were associated with longer sleep latency. Evening screen exposure and napping were also associated with higher frequencies of nocturnal awakenings.
A protective effect of morning exercise was demonstrated on sleep quality, sleep latency, and nocturnal awakenings. Alcohol misuse impairs sleep whereas physical activity enhances it in the ordinary population.
Evening caffeine consumption and reporting dinner as the largest meal were associated with shorter sleep duration and longer sleep latency.
Melatonin is a naturally produced hormone by the pineal gland that regulates the sleep-wake cycle and improves sleep quality, onset, and duration. With its sleep-regulatory role, melatonin is frequently used as a therapeutic for insomnia in clinics.
Melatonin itself is not a herb with a classical traditional-medicine history; its role as a natural bodily hormone was identified in the 20th century. However, foods rich in melatonin β such as cherries, walnuts, and almonds β have long been components of dietary traditions in many cultures. Foods that are particularly rich sources of melatonin include fruits and nuts, specifically tart cherries, tomatoes, strawberries, almonds, and walnuts.
A meta-analysis (19 studies, 1,683 subjects) found that melatonin demonstrated significant efficacy in reducing sleep latency (WMD = 7.06 minutes [95% CI 4.37 to 9.75], p<0.001) and increasing total sleep time (WMD = 8.25 minutes, p=0.013). Trials with longer duration and higher doses of melatonin demonstrated greater effects on decreasing sleep latency and increasing total sleep time. Overall sleep quality was significantly improved in subjects taking melatonin.
The effects of melatonin were modest but did not appear to dissipate with continued use. Although the absolute benefit compared to placebo is smaller than other pharmacological treatments for insomnia, melatonin may have a role in treatment given its relatively benign side-effect profile.
A dose-response meta-analysis (26 RCTs, 1,689 observations) showed that melatonin gradually reduces sleep onset latency and increases total sleep time, peaking at 4 mg/day. Insomnia status and the time between treatment administration and the sleep episode were significant predictors of sleep onset latency.
In a subgroup analysis of a population with delayed sleep phase syndrome, the average reduction in sleep onset latency was 38.8 minutes, which is both clinically and statistically significant.
In adults, melatonin was significantly better in improving sleep onset latency measured with diary when pooling RCTs across sleep disorders, and was particularly effective for delayed sleep phase disorder.
Evidence strength: Moderate to strong for delayed sleep phase syndrome; modest but consistent for general primary sleep disorders. Effects are statistically significant but may be of limited clinical magnitude in unselected insomnia populations.
Valerian (Valeriana officinalis L.) is a popular herbal medicine used as a sleep aid. It has been used in traditional European herbalism and in Ayurvedic practice for centuries as a nervine and sedative, typically prepared as a decoction or tincture from the dried root.
The available evidence suggests that valerian might improve sleep quality without producing side effects. However, the overall picture from systematic reviews is inconsistent. An extensive literature search identified 16 eligible studies examining a total of 1,093 patients. Most studies had significant methodologic problems, and the valerian doses, preparations, and length of treatment varied considerably. A dichotomous outcome of sleep quality reported by 6 studies showed a statistically significant benefit (relative risk of improved sleep = 1.8, 95% CI, 1.2β2.9), but there was evidence of publication bias. The available evidence suggests valerian might improve sleep quality without producing side effects.
A meta-analysis of 18 randomized placebo-controlled trials, published in 2010, concluded that valerian's effectiveness had not been demonstrated with quantitative or objective measures, although valerian could improve subjective sleep quality.
The qualitative dichotomous results from meta-analysis suggest that valerian would be effective for a subjective improvement of insomnia, although its effectiveness has not been demonstrated with quantitative or objective measurements.
Popular herbal remedies with a long-standing history of traditional medicinal use, namely valerian root extracts, lack adequate support to justify their use in individuals experiencing sleep disorders, according to a 2025 narrative review in Nutrition Reviews.
Evidence strength: Weak to mixed. Subjective improvement has been reported in some trials, but objective improvement has not been consistently demonstrated. Most studies have significant methodological limitations. Current systematic literature does not robustly support valerian for sleep onset.
Tryptophan-rich foods such as warm milk, turkey, and certain seeds have been used in various folk traditions to promote sleep, though these uses predate scientific understanding of tryptophan's biochemistry.
Tryptophan is an essential amino acid that serves as a precursor for the synthesis of serotonin and melatonin, two neurotransmitters involved in sleep regulation. Serotonin plays a key role in mood, anxiety, and sleep-wake cycles, whereas melatonin regulates sleep timing and wakefulness. The primary mechanism by which tryptophan improves sleep is through its conversion to serotonin and melatonin in the brain.
Although a few studies have reported significant improvements in sleep quality and duration following tryptophan supplementation, others have not. Therefore, evidence for the efficacy of tryptophan as a sleep aid is mixed, and more research is needed to establish its optimal dose and duration for the treatment of insomnia. Tryptophan supplements appear safe at the recommended doses, but high doses should be avoided because of the risk of serious adverse effects.
Dietary sources of tryptophan include poultry, eggs, cheese, nuts, and seeds.
Evidence strength: Preliminary and mixed. Biochemical plausibility is well-established; however, clinical evidence from human RCTs is inconsistent, and more high-quality trials are needed.
Magnesium-rich foods and mineral-rich spring waters have historically been associated with relaxation and calm in various European spa and naturopathic traditions, though formal use of magnesium specifically for sleep onset is a modern application.
Tryptophan is a precursor to the neurotransmitter serotonin and the neurosecretory hormone melatonin, both of which are associated with sleep and alertness. Tryptophan can also regulate sleep and the circadian rhythm by increasing melatonin levels. Several studies have demonstrated that magnesium exerts a relaxant effect.
In sleep studies, magnesium oxide, magnesium citrate or magnesium L-aspartate were used as interventions, while magnesium glycinate and magnesium threonate are widely used in clinical practice.
Blood magnesium level was related to total sleep time. In a multi-ingredient study, a nutritional blend consisting of tryptophan, glycine, magnesium, tart cherry powder, and L-theanine shortened sleep onset latency (P=0.002), increased total sleep time (P=0.01), improved sleep efficiency (P=0.03), and reduced morning drowsiness (P=0.02). However, isolating magnesium's individual contribution in such combination studies is not possible from that data alone.
Melatonin, magnesium, and zinc have been studied for their potential roles in sleep regulation, but further research is needed to establish their optimal use in the treatment of insomnia.
Evidence strength: Preliminary. Evidence for isolated magnesium supplementation on sleep onset latency in otherwise healthy adults is limited. Deficiency states may be more strongly linked to impaired sleep. Multi-ingredient studies are confounded by combination effects.
L-Theanine is an amino acid found primarily in green tea (Camellia sinensis), with potential relaxation and sleep-promoting effects. Green tea has been consumed for thousands of years in East Asian traditions β particularly in Chinese, Japanese, and Korean cultures β and is historically associated with a state of calm alertness. Green tea is the primary dietary source of theanine, with levels ranging from 0.9% to 3.1% of the dry weight of tea leaves.
Theanine is structurally similar to the neurotransmitter glutamate and has been shown to cross the blood-brain barrier and influence brain function. L-theanine, particularly its various complexes with magnesium, increases the expression of GABAergic, serotonergic, and glutamatergic receptors, which were associated with decreased ECoG frequency, increased amplitude, and enhanced delta wave powers in animal models.
L-theanine demonstrates potential to improve sleep onset latency and overall sleep quality through GABA modulation. L-theanine and glycine seem to present promising sleep-promoting properties according to a 2025 narrative review in Nutrition Reviews. Experimental models in rats have demonstrated that L-theanine, consumed together with either magnesium or GABA, has a positive effect on sleep quality and duration, although no clinical studies that investigated this synergistic relationship in human cohorts are currently available.
Evidence strength: Promising but preliminary. Some mechanistic and animal data support plausibility; human clinical evidence specifically targeting sleep onset latency remains limited. Theanine appears safe and does not cause daytime drowsiness in existing studies.
Glycine is a non-essential amino acid found in collagen-rich foods such as bone broth and gelatin. Its deliberate use as a sleep supplement is modern, with no established traditional context.
In human studies, glycine ingestion improved sleep quality and shortened latency to sleep onset and slow wave sleep without changing sleep architecture. L-theanine and glycine seem to present promising sleep-promoting properties, and glycine was a component of the multi-ingredient blend that significantly improved sleep onset latency in at least one clinical trial. Human evidence is, however, still limited to a small number of trials.
Evidence strength: Preliminary. Small human trials show signals for shortened sleep onset and improved sleep quality. Larger, independent RCTs are needed.
Tart cherry (Prunus cerasus) is a fruit rich in various bioactive compounds, including melatonin and tryptophan, serotonin, and proanthocyanidins. Sour cherries have a long culinary and medicinal history in Central and Eastern European folk medicine, where they were used for general recuperation and calming, though their specific association with sleep is a contemporary observation.
The primary mechanism of action is believed to be related to the high melatonin content of tart cherries, which helps regulate the sleep-wake cycle. Tart cherries contain tryptophan, serotonin, and melatonin. One randomized, double-blind, placebo-controlled crossover study of healthy middle-aged and elderly men and women tested the effect of seven different Jerte Valley cherry cultivars consumed as fresh fruit on total urinary melatonin and sleep parameters. Intake of all cultivars at a level of 200 g/day, twice daily for 3 days, increased urinary 6-sulfatoxymelatonin in both middle-aged and elderly adults.
In all available clinical studies on tart cherry juice and sleep, the treatment dose corresponded to 200β300 g of fresh cherries per day, whose melatonin and tryptophan content is estimated at 0.27β0.40 ΞΌg and 18β27 ΞΌg, respectively β far below the 0.5β5 mg (melatonin) and 1.2β2.4 g (tryptophan) typically required for sleep-promoting effects. Therefore, it is unlikely that the observed benefits result directly and exclusively from the supply of these specific compounds, and further investigations into possible alternative and/or complementary mechanisms are required.
In the meantime, chronic supplementation with tart cherry juice appears to be a safe and potentially effective dietary strategy to support restorative sleep.
Evidence strength: Moderate signal from small RCTs. Mechanistic basis is not fully clarified; benefits likely involve multiple bioactive constituents beyond melatonin alone. Sample sizes in most studies are small.
Hops have been used in European herbal medicine since at least the 9th century as a mild sedative and sleep-promoting nervine. Traditional preparations include hop pillow aromatherapy (inhalation of hop strobiles), hop teas, and tinctures. Hops are also frequently combined with valerian in traditional European phytotherapy.
Findings from a literature review suggest that certain supplements, particularly valerian, hops, and melatonin, could be effective in improving sleep quality and reducing insomnia symptoms through modulation of neurotransmitter systems and regulation of sleep-wake cycles. These supplements function through various mechanisms, such as modulating GABA and serotonin receptors, promoting relaxation, and regulating sleep-wake cycles. Clinical trials have shown some promise for hops, although evidence remains limited and more research is needed.
Evidence strength: Weak to preliminary. Most positive data involves combinations (notably hops-valerian), making it difficult to isolate hops' individual contribution. Independent, well-designed RCTs are limited.
Chamomile is one of the oldest and most widely used medicinal plants in European and Mediterranean folk traditions. Used for centuries as a tisane (herbal tea) to promote calm and sleep, it appears in ancient Egyptian, Greek, and Roman records as a calming and digestive herb. Chamomile tea remains among the most widely consumed herbal beverages worldwide.
The active constituent associated with chamomile's calming and potential sleep effects is apigenin, a flavonoid that binds to benzodiazepine receptors in the brain. The current body of literature converges to suggest that melatonin, magnesium, omega-3 fatty acids, tart cherry juice, kiwifruit, and apigenin-containing chamomile subjectively and objectively improve several sleep-related parameters and outcomes in young, older, and clinical cohorts.
German chamomile has shown limited evidence to support its efficacy in clinical trials. Most available studies are small with methodological limitations.
Evidence strength: Weak to preliminary. Mechanistic plausibility via apigenin is reasonable; clinical evidence for sleep onset specifically is sparse and inconsistent.
Ashwagandha is a cornerstone adaptogen of Ayurvedic medicine, used for over 3,000 years in traditional Indian medicine. It is classified as a rasayana (rejuvenating tonic) and has been traditionally prescribed as a root powder in warm milk to promote sleep, reduce stress, and restore vitality.
Ashwagandha, myoinositol, Rhodiola rosea, and phosphatidylserine may be considered as subsidiary sleep aids by working in synergy with other soporific nutrients or by addressing concomitant physiological mechanisms that may disrupt healthy sleepβwake patterns by indirect routes.
Evidence strength: Preliminary. Some small RCTs report improvements in sleep quality and onset, likely via stress and cortisol modulation. High-quality, large-scale RCTs targeting sleep onset specifically are lacking.
Kiwifruit is not associated with classical herbal traditions for sleep. Its identification as a sleep-relevant food is a recent development in nutritional research.
The current body of literature converges to suggest that kiwifruit subjectively and objectively improves several sleep-related parameters and outcomes in young, older, and clinical cohorts. Small controlled trials in adults have reported reduced sleep onset latency following kiwifruit consumption, and mechanisms proposed include serotonin precursor content and antioxidant activity, though these remain to be fully established.
Evidence strength: Preliminary. Limited to a small number of human trials; larger RCTs are warranted.
Several researchers have explored synergistic combinations of the above nutrients. One study investigated nutritional modulation of sleep latency in 16 participants over 3 days. The intervention group received a combination of 1,000 mg of tryptophan, 3,000 mg of glycine, 300 mg of magnesium, 220 mg of tart cherry powder, and 200 mg of L-theanine. This novel nutritional blend shortened sleep onset latency (P=0.002), increased total sleep time (P=0.01), improved sleep efficiency (P=0.03), and reduced morning drowsiness (P=0.02). The small sample size limits generalizability.
A systematic meta-analysis of 24 studies found that caffeine consumption increased sleep onset latency by approximately 9 minutes, reduced total sleep time by 45 minutes, and reduced sleep efficiency by 7%. To avoid reductions in total sleep time, coffee (approximately 107 mg caffeine per 250 mL) should be consumed at least 8.8 hours prior to bedtime. Caffeine is the most commonly considered component of sleep hygiene, appearing in 51% of published sleep hygiene studies.
Sleep onset latency data from controlled studies shows that intoxicating doses of alcohol can modestly reduce SOL by approximately 5 minutes at doses β₯0.9 g/kg, while the average SOL for no-dose nights in rested, healthy controls was around 15 minutes. Despite this apparent short-term facilitation of sleep onset, alcohol decreases sleep efficiency and increases wake after sleep onset. It increases slow-wave sleep in the first half of the night, with the inverse occurring in the second half.
Two meta-analyses found that acute exercise produces modest increases in PSG-assessed total sleep time, NREM stage 2 sleep, slow-wave sleep, and latency to REM sleep. A protective effect of morning exercise was specifically demonstrated on sleep quality, sleep latency, and nocturnal awakenings.
Evening screen exposure was associated with longer sleep latency and higher frequencies of nocturnal awakenings. Recommendations to promote sleep quality and prevent sleep-related problems should include engaging in regular exercise, preferably in the morning, and avoiding naps, heavy meals close to bedtime, caffeine, smoking, and evening screen exposure.
Reporting dinner as the largest meal of the day and evening caffeine consumption was associated with shorter sleep duration and longer sleep latency.
Dietary sources of tryptophan include poultry, eggs, cheese, nuts, and seeds. Tryptophan can regulate sleep and the circadian rhythm by increasing melatonin levels, providing a plausible mechanistic link between diet and sleep onset.
The melatonin content of foods has been better characterized than serotonin content. Foods that are particularly rich sources of melatonin include fruits and nuts, specifically tart cherries, tomatoes, strawberries, almonds, and walnuts. Tart cherries are of particular interest in sleep research because they contain tryptophan, serotonin, and melatonin.
5-HTP is a direct precursor to serotonin, which is further converted to melatonin, making it mechanistically relevant to sleep onset. Animal research shows it shortens NREM sleep latency and restores sleep after serotonin depletion. Clinical evidence includes improved sleep stability in a crossover RCT in Parkinson's disease patients and reduced sleep terror frequency in children.
Ashwagandha (Withania somnifera) root extract has been used in Ayurvedic medicine for millennia as a Rasayana (rejuvenator) and sleep promoter. Multiple recent double-blind RCTs demonstrate significant improvements in sleep onset latency, total sleep time, and sleep efficiency, with the NIH ODS confirming this evidence.
Preclinical data show that both essential oil and saponin fractions of Semen Platycladi significantly shorten sleep onset time in PCPA-induced insomnia mice. The mechanism involves upregulation of serotonergic and GABAergic receptor systems. This supports the traditional TCM claim of biota seed as a sedative herb that facilitates sleep initiation.
California poppy has documented effects on sleep latency in human observational and animal studies. An open-label observational study (Abdellah et al., J Trad Complement Med 2019) using a combination with valerian in 36 insomnia patients showed significant reduction in insomnia severity and increased sleep duration after 4 weeks. Animal data show sleeping induction at doses above 100 mg/kg (Rolland et al. 1991). The EMA recognizes it as a traditional herbal medicine for mild sleep disturbances. A Phase 3 RCT (NCT06795776, 104 participants) has been conducted, though results are pending publication.
Chamomile (Matricaria chamomilla) is one of the most widely used traditional sleep herbs. Its key active compound, apigenin, binds to GABA-A receptors, producing sedative effects. RCTs in older adults and insomnia patients show modest improvements in sleep quality and sleep-onset-related parameters, though a pilot RCT in primary insomnia found moderate but non-significant sleep latency reductions.
Animal models demonstrate that P. cocos extracts reduce sleep latency and counteract caffeine-induced wakefulness, consistent with facilitation of sleep onset. The GABAergic mechanism of pachymic acid (BZD binding site activation) provides a plausible biological pathway for sleep onset facilitation.
GABA is the primary inhibitory neurotransmitter of the CNS and a central target for virtually all pharmacological hypnotic drugs. Exogenous GABA supplementation and GABA combined with L-theanine have been shown in controlled studies to decrease sleep latency and improve NREM sleep in animal and human research.
Preclinical studies demonstrate that Ganoderma extract significantly shortens sleep latency (time to fall asleep) through GABAergic and serotonergic mechanisms, and via gut microbiota-mediated serotonin signalling. Traditional Chinese medicine describes a sedative 'An-Shen' effect for insomnia.
Gastrodin's upregulation of endogenous GABA synthesis via GAD and sodium channel blocking properties are well-supported mechanisms for sleep-onset promotion in animal studies. Traditional use specifically cites GE for insomnia accompanying head tension. Evidence is predominantly animal-based.
Glycine is a non-essential amino acid that promotes sleep onset by acting on NMDA receptors in the suprachiasmatic nucleus to facilitate the core body temperature drop required for sleep initiation. Controlled clinical trials in humans show 3 g of glycine before bedtime significantly reduces sleep onset latency and improves subjective sleep quality with PSG confirmation.
Hops (Humulus lupulus) cone is approved by the German Commission E for sleep disturbances associated with anxiety or restlessness. It acts primarily via GABAergic mechanisms and has binding affinities for melatonin and serotonin receptors. Clinical evidence most consistently supports sleep improvement when combined with valerian, with sleep latency and quality significantly improved.
Jujube seed extract (Semen Ziziphi Spinosae) has the strongest evidence base of all jujube uses, grounded in both preclinical and small clinical studies. Key bioactive compounds spinosin and jujubosides modulate GABA-A receptors and the serotonin (5-HT1A) pathway, producing sedative effects. A review of pharmacological effects cited two small clinical studies supporting a role in insomnia management. Robust large-scale RCTs remain lacking.
A 3-week RCT in 21 middle-aged adults found that 25 mg/day Zembrin improved subjective sleep onset compared to placebo. Traditional use included giving fresh kanna juice to induce sleep in young children. Melatonin receptor activation has also been proposed as a contributing mechanism.
Kava (Piper methysticum) root contains kavalactones that modulate GABA-A receptors and voltage-gated sodium and calcium channels, producing anxiolytic and sedative effects. Clinical research shows decreased sleep latency, improved sleep quality, and anxiolytic benefits in insomnia; however, hepatotoxicity concerns limit its clinical recommendation.
Controlled clinical trials and polysomnographic studies demonstrate that 3 g of glycine before bedtime shortens sleep onset latency and reduces time to slow-wave sleep. The mechanism involves NMDA receptor-mediated activation in the suprachiasmatic nucleus, inducing peripheral vasodilation and a drop in core body temperature that facilitates rapid sleep initiation.
L-Theanine is an amino acid from tea (Camellia sinensis) that promotes relaxation without sedation by modulating glutamate and GABA receptors and increasing alpha brain wave activity. A 2025 systematic review and meta-analysis found L-theanine supplementation showed positive effects on subjective measures of sleep onset latency and overall sleep quality.
L-Tryptophan is the essential amino acid precursor to serotonin and melatonin. Clinical evidence shows it reduces the time to fall asleep at doses of 1 g or more. A meta-analysis of 18 studies found tryptophan supplementation significantly reduced wake-after-sleep-onset, and situational insomnia with difficulty falling asleep responded rapidly at various doses.
Lavender (Lavandula angustifolia) is approved by the German Commission E for sleep disturbances associated with anxiety. Oral lavender oil (Silexan, 80 mg) has demonstrated efficacy in multiple RCTs, improving sleep quality and reducing anxiety-related insomnia. Inhaled lavender aromatherapy also shows sleep-promoting effects across multiple populations.
Multiple clinical trials support lemon balm's ability to improve sleep onset and quality. Rosmarinic acid inhibits GABA transaminase, raising brain GABA levels and promoting sedation. Both solo extracts and valerian combinations have demonstrated statistically significant improvements in sleep parameters. The European Medicines Agency (EMA) and the German Commission E recognize lemon balm for nervous sleeping disorders.
Nelumbo nucifera seed extract has been shown to decrease sleep onset latency in rodent models through GABAergic mechanisms. Neferine synergizes with thiopental to enhance sleep induction. Traditional use in East Asia documents lotus seeds as an aid to falling asleep.
Magnesium is an essential mineral that regulates NMDA glutamate receptors and GABA-A receptors, both central to sleep regulation. A systematic review and meta-analysis found magnesium supplementation reduced sleep onset latency by 17.36 minutes versus placebo in older adults with insomnia, though evidence quality was rated low-to-moderate.
Honokiol and magnolol reduce sleep latency in preclinical models via GABA-A receptor modulation at the benzodiazepine site. Human evidence from combination-product RCTs (particularly the 634-woman and 89-woman menopausal trials) shows improved sleep initiation. Typical doses used in human studies range from 60β250 mg/day of standardized extract.
Melatonin is the most extensively studied natural sleep-onset agent. Multiple meta-analyses of RCTs confirm it reduces sleep onset latency (SOL) by approximately 7β10 minutes on average, with the largest effects seen in delayed sleep phase disorder (up to ~39 minutes SOL reduction). A dose-response meta-analysis of 26 RCTs found benefits peak at around 4 mg/day.
Preclinical studies demonstrate that Semen Platycladi (P. orientalis seed) essential oil and saponins significantly shorten sleep onset time in PCPA-induced insomnia mouse models. This effect is attributed to upregulation of serotonergic and GABAergic neurotransmission.
Passionflower (Passiflora incarnata) has traditional use as a sedative herb and demonstrates GABAergic activity. A double-blind placebo-controlled RCT of passionflower herbal tea showed significant improvement in subjective sleep quality in healthy adults. It is often combined with valerian and hops for sleep support, where the combination showed improved sleep latency.
Preclinical studies consistently show that P. tenuifolia polygalasaponins reduce sleep latency (time to sleep onset) in pentobarbital-treated and PCPA-induced insomnia mouse models, supporting the TCM use of Yuan Zhi for difficulty falling asleep.
Progesterone's metabolite allopregnanolone produces sedative effects in humans, facilitating sleep onset. Oral micronized progesterone produces sedation via GABA-A modulation, a mechanism replicated in multiple human pharmacology studies. This effect is leveraged clinically by prescribing oral micronized progesterone at bedtime.
Wang & Wang (2022) demonstrated reishi supplementation in 60 chronic insomnia patients significantly reduced sleep onset time (sleep latency). The 2026 SLEEP 8-week RCT also captured sleep onset as part of the ISI outcome, with reishi outperforming melatonin. GABAergic sedative-adjacent activity is the primary proposed mechanism for accelerating sleep onset.
Saffron (Crocus sativus) and its active compounds crocin and safranal have been evaluated in multiple RCTs for sleep quality. A 2025 large decentralized RCT found saffron extract (20β30 mg) significantly reduced insomnia symptoms versus placebo, with the most pronounced effects on sleep induction specifically.
Preclinical studies show A. julibrissin shortens sleep-onset latency in rodents. GABAergic and serotonergic mechanisms have been identified for several constituents. Traditional use as a sedative that aids the transition to sleep is well-documented in TCM.
The 2025 BlueCALM crossover RCT in primary insomnia patients showed improved sleep parameters, including sleep initiation, with 400 mg/day S. lateriflora extract versus placebo. GABAergic and cortisol-suppressive mechanisms provide biological plausibility for a sedative-onset effect.
The Leeds Sleep Evaluation Questionnaire used in the Hausenblas et al. (2024) RCT includes a sleep onset subscale; MgT supplementation showed benefits for ease of getting to sleep in adults with self-reported sleep problems. The GABAergic and NMDA-modulating mechanisms of brain magnesium are consistent with reduced sleep-onset latency.
Valerian (Valeriana officinalis) root extract has been used since antiquity for insomnia and nervous tension, and is approved by the German Commission E for sleep disturbances due to nervousness. Multiple RCTs and meta-analyses report improved sleep quality and reduced sleep latency, though evidence quality is variable. The 2020 systematic review and meta-analysis (Shinjyo et al.) found significant benefit across 36 RCTs.
Gardenia jasminoides is traditionally used in TCM formulas for insomnia, including Zhi-zi-chi decoction, for difficulty falling asleep associated with heart fire and restlessness. Preclinical evidence shows geniposide and gardenoside have sedative properties in animal models. The 2010 crocetin human trial did not measure sleep onset latency specifically.
Traditional TCM use of Polygala root includes facilitating sleep onset in insomnia. The root's GABAergic and serotonergic mechanisms, and its documented sedative properties in preclinical models, are directly relevant to the process of falling asleep.
Poppy preparations have been used across multiple traditional medicine systems to hasten sleep onset. Both opioid (P. somniferum) and milder sedative (P. rhoeas, E. californica) species are implicated. The California poppy supplement form shows preliminary human evidence in combination with valerian for reducing sleep latency.
Sceletium has an ethnobotanically documented history of use as a soporific. Historical records from 1898 describe fresh sceletium juice being given to young children to rapidly induce deep sleep. The sedative/hypnotic property is one of the plant's traditional roles, but no clinical trial has specifically measured sleep latency as a primary endpoint.
SJW has been used traditionally for insomnia and sleep disturbances. The available polysomnographic clinical data showed no significant improvement in sleep onset latency. Its traditional use for nervousness and restlessness underpins the historical sleep indication, especially where anxiety or low mood impairs sleep onset.
Go back